Shelf-Stable Future: Why We Want Blood and Batteries on Demand

The latest edition of MIT Technology Review's The Download flagged two seemingly unrelated quests: the US military's $73 million effort to create dried, shelf-stable blood, and the ongoing race to reinvent batteries. On the surface, one saves lives on the battlefield, the other powers your phone. But as a starting point for a bigger conversation, they point to the same modern obsession.

In my view, we are entering an era where we are no longer satisfied with harvesting nature's resources. We want to decouple from them entirely. We want blood without donors and energy without degradation. And that desire, while deeply human, comes with complications we are not talking about enough.

The Problem With Real Blood Is That It's Too Real

To understand why the Department of Defense is spending tens of millions to fake blood, you have to appreciate how inconvenient real blood is. This is not a critique; it's biology.

Real blood is alive, even outside the body. Red cells need refrigeration and last only about 42 days. Platelets, which are critical for clotting, last just five to seven days and must be kept at room temperature while constantly agitated. Plasma can be frozen, but then you need freezers and time to thaw it. Every unit requires a donor, testing, a cold chain, and a ticking clock.

As highlighted in the source report, that logistical fragility has a human cost. In 2007, a helicopter ferrying blood to a field hospital in Iraq was shot down, killing its crew. It was a stark illustration that the supply chain itself can be a casualty. DARPA's current program aims to solve this by creating dried versions of plasma, platelets, and red blood cells that could be stored for months or years at room temperature and rehydrated in minutes, with a goal of field deployment by 2029.

It sounds like science fiction, but the concept is old. We have been trying to make blood substitutes since the 1980s. The difference now is we are not just trying to mimic oxygen-carrying capacity with chemicals like perfluorocarbons or hemoglobin-based oxygen carriers, many of which failed trials due to toxicity and blood pressure spikes. We are trying to preserve the actual biological components in a desiccated state.

Think of Blood Like Fresh Produce

A useful analogy is food preservation. For most of human history, food was local and perishable. Then we invented canning, freezing, and freeze-drying. That allowed us to ship calories across continents and store them for years.

Blood banking is still stuck in the "fresh produce" era. We have refrigeration, which is like putting lettuce in the fridge, it buys you a little time. What DARPA wants is the equivalent of freeze-dried coffee for blood: lightweight, shelf-stable, just add water. If you can do that, you don't just help soldiers. You transform rural medicine, disaster relief, and ambulance care worldwide.

But here's my contrarian take: the fact that we have failed for so long should make us humble. Blood is not one product. It's a tissue, an organ in liquid form. It carries oxygen, fights infection, clots wounds, regulates pH, and communicates with the immune system. Drying it without destroying those delicate functions is like trying to dehydrate an egg and then expecting it to hatch after you add water. You might get the proteins and fats back, but will you get the life?

Batteries and Blood Want the Same Thing

This is where the second topic from that newsletter, the future of batteries, becomes a perfect mirror.

What is a battery, if not a way to make energy shelf-stable? Solar and wind are intermittent, like blood donations. They come in surges. The grid, like a trauma patient, needs energy exactly when and where it is needed. Our current lithium-ion batteries are the equivalent of refrigerated blood: better than nothing, but heavy, degradable, temperature-sensitive, and dependent on a fragile supply chain of mining and refining.

The entire battery industry is now chasing its own version of "dried blood." Solid-state batteries, sodium-ion chemistries, iron-air storage, all are attempts to create energy storage that is denser, cheaper, longer-lasting, and less dependent on scarce materials like cobalt and nickel. The goal is the same: decouple availability from the moment of creation.

I find this parallel revealing. In both fields, we are trying to conquer time and decay. We don't want to be hostage to biology's 42-day expiration date or electrochemistry's capacity fade. We want to bottle the function and shelve it indefinitely. It is a profoundly modern ambition, and it explains why both projects attract billions in funding despite decades of disappointment.

The question is whether we are solving the right problem. For batteries, some argue we should focus less on a miracle chemistry and more on smarter grids, less consumption, and better use of what we have. For blood, some argue we should focus on better logistics, drones, walking blood banks, and expanded donor pools rather than engineering a powder.

Why Is the Military Building Our Medical Future?

This is the part of the fake blood story that makes me most uncomfortable, and it deserves an opinionated look.

There is a long, proud history of military medicine driving civilian breakthroughs. Trauma surgery, vascular repair, helicopter medevac, and tourniquet use all matured on the battlefield before reaching your local ER. If DARPA succeeds, the civilian spillover will be enormous. A clinic in rural Alaska or sub-Saharan Africa that cannot maintain a cold chain could keep dried platelets in a cupboard for a year. That is genuinely revolutionary.

But we should be honest about the incentives. The military does not want shelf-stable blood primarily to help remote clinics. It wants it for what strategists call "distributed operations" and "contested logistics." In a future conflict in the Pacific, for example, you cannot assume air superiority to fly in blood or secure refrigeration near the front line. Dried blood is a tool for fighting wars where supply lines will be attacked.

That matters because military-led development prioritizes different things than public health-led development. Speed, ruggedness, and performance under extreme stress will be optimized. Long-term safety, cost-effectiveness for civilian health systems, and equitable access may be secondary. We have seen this before. Will a product designed for a 25-year-old soldier with a blast injury be safe and affordable for a 70-year-old with a gastrointestinal bleed or a child with sickle cell disease?

History also urges caution. The rush to deploy hemoglobin-based oxygen carriers in the 1990s and 2000s led to clinical trials that were later criticized for ethical concerns, including testing on trauma patients who could not consent. If the push to meet a 2029 deployment goal creates pressure to cut corners, the fallout will erode trust in both military and civilian medicine.

The Ethical and Practical Hangover

Let us assume, for a moment, that the science works perfectly. We get a powder that, when mixed with sterile water, becomes fully functional red cells that circulate for weeks, platelets that clot, and plasma that carries clotting factors. Even then, we inherit a new set of problems.

First, what does this do to blood donation as a civic act? Voluntary donation is one of the last truly altruistic systems at scale. People give a part of themselves, for free, to a stranger. If we can manufacture blood, does that system wither? And if the manufactured product is expensive and patented, do we replace an altruistic shortage with a commercial one? Imagine a world where natural blood is for the rich and synthetic blood is for everyone else, or vice versa.

Second, there is the risk of overconfidence. Shelf-stable blood could encourage riskier operational planning. If commanders believe blood is now abundant at the front, will they accept missions with higher casualty risks? In civilian life, will hospitals in remote areas delay transfers because they feel they have blood on hand, even if definitive surgical care is hours away?

Third, for batteries, the parallel ethical question is about resource extraction. We want to escape lithium and cobalt dependency partly for environmental and human rights reasons. But every new chemistry brings its own mining footprint, whether it is sodium, iron, or solid electrolytes that require rare ceramics. We are not eliminating extraction; we are just moving the shovel to a different part of the earth.

So, Should We Cheer for Fake Blood?

My answer is a qualified yes, but with eyes open.

I am optimistic because the underlying science of lyophilization, or freeze-drying, has already worked for plasma. French and German militaries have used freeze-dried plasma for years. The US FDA has approved some freeze-dried plasma products. Drying platelets and especially red cells is an order of magnitude harder because cell membranes do not like being dehydrated, but advances in cryoprotectants, trehalose sugars that desert plants use to survive drying, and novel preservation techniques make this the most plausible attempt yet.

The real breakthrough will not be a single product but a platform for stabilizing biology. If we can dry blood cells, we can potentially dry other cell therapies, like CAR-T cells for cancer, or lab-grown tissues. That is a foundational technology.

Similarly, even if solid-state batteries do not deliver the 1,000-mile EV range that headlines promise, incremental improvements in shelf-stability, safety, and cost will still reshape the grid.

But we should not fall for the narrative that technology will make logistics disappear. A bag of dried blood still needs sterile water, trained hands, and a correct diagnosis. A better battery still needs a grid to charge it and a society willing to build transmission lines.

The most honest way to view both quests is not as replacements for nature, but as buffers against its volatility. We will still need donors. We will still need power plants. What we are buying is time, the ability to keep the essence of blood and energy intact until the moment they are needed most.

If DARPA and battery researchers can give us that time without creating new inequalities or illusions of invulnerability, then faking blood and reinventing batteries will be more than just technical wins. They will be moral ones.

This article was inspired by reporting from MIT Technology Review's The Download newsletter covering DARPA's dried blood program and battery innovation. Source: MIT Technology Review.

____________

This article was created by an AI writer using the topic ideas from this post => https://www.technologyreview.com/2026/10/14/1146452/the-download-military-fake-blood-future-batteries/